Hereditary palmoplantar keratoderma
MONDO:0019272An instance of palmoplantar keratosis that is caused by an inherited modification of the individual's genome.
Also known as: hereditary PPK, hereditary keratosis palmoplantaris, hereditary palmoplantar hyperkeratosis, hereditary palmoplantar keratosis
13 clinical trials for this condition and its sub-types, 0 tagged with Hereditary palmoplantar keratoderma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hereditary palmoplantar keratoderma
-
Diffuse palmoplantar keratoderma 0 trials · 12 incl. sub-types
32 sub-types
- Papillon-Lefevre disease 5 trials
- Corneal intraepithelial dyskeratosis-palmoplantar hyperkeratosis-laryngeal dyskeratosis syndrome 4 trials
- Odonto-onycho-dermal dysplasia 2 trials
- Epidermolytic palmoplantar keratoderma, 1 1 trial
- Bart-Pumphrey syndrome 0 trials
- CEDNIK syndrome 0 trials
- Clouston syndrome 0 trials
- Curly hair - acral keratoderma - caries syndrome 0 trials
- Haim-Munk syndrome 0 trials
- KID syndrome 0 trials Sub-types →
- Naegeli-Franceschetti-Jadassohn syndrome 0 trials
- Schöpf-Schulz-Passarge syndrome 0 trials
- Autosomal dominant palmoplantar keratoderma and congenital alopecia 0 trials
- Autosomal recessive palmoplantar keratoderma and congenital alopecia 0 trials
- Dermatopathia pigmentosa reticularis 0 trials
- Diffuse nonepidermolytic palmoplantar keratoderma 0 trials
- Diffuse palmoplantar keratoderma - acrocyanosis syndrome 0 trials
- Diffuse palmoplantar keratoderma with painful fissures 0 trials
- Erythrokeratodermia variabilis 0 trials Sub-types →
- Hearing loss with skin disease 0 trials
- Hereditary palmoplantar keratoderma, Gamborg-Nielsen type 0 trials
- Hypohidrosis-enamel hypoplasia-palmoplantar keratoderma-intellectual disability syndrome 0 trials
- Keratosis palmaris et plantaris-clinodactyly syndrome 0 trials
- Loricrin keratoderma 0 trials
- Mal de Meleda 0 trials
- Palmoplantar keratoderma, Bothnian type 0 trials
- Palmoplantar keratoderma, Nagashima type 0 trials
- Palmoplantar keratoderma-XX sex reversal-predisposition to squamous cell carcinoma syndrome 0 trials
- Palmoplantar keratoderma-deafness syndrome 0 trials
- Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome 0 trials Sub-types →
- Palmoplantar keratoderma-sclerodactyly syndrome 0 trials
- Skin fragility-woolly hair-palmoplantar keratoderma syndrome 0 trials
-
Olmsted syndrome 1 trial
3 sub-types
- Olmsted syndrome 1 0 trials
- Olmsted syndrome 2 0 trials
- Olmsted syndrome, X-linked 0 trials
-
Focal palmoplantar keratoderma 0 trials · 1 incl. sub-types
12 sub-types
- Pachyonychia congenita 1 trial Sub-types →
- Focal palmoplantar and gingival keratoderma 0 trials
- Focal palmoplantar keratoderma with joint keratoses 0 trials
- Hereditary painful callosities 0 trials
- Hypotrichosis-osteolysis-periodontitis-palmoplantar keratoderma syndrome 0 trials
- Isolated focal non-epidermolytic palmoplantar keratoderma 0 trials
- Nail and teeth abnormalities-marginal palmoplantar keratoderma-oral hyperpigmentation syndrome 0 trials
- Palmoplantar keratoderma, nonepidermolytic, focal 1 0 trials
- Palmoplantar keratoderma-esophageal carcinoma syndrome 0 trials
- Striate palmoplantar keratoderma 0 trials Sub-types →
- Tyrosinemia type II 0 trials
- Wooly hair-palmoplantar keratoderma syndrome 0 trials
-
Palmoplantar keratoderma, epidermolytic 0 trials · 1 incl. sub-types
2 sub-types
-
Punctate palmoplantar keratoderma 0 trials
4 sub-types
- Focal acral hyperkeratosis 0 trials
- Punctate palmoplantar keratoderma type 1 0 trials Sub-types →
- Punctate palmoplantar keratoderma type 2 0 trials
- Punctate palmoplantar keratoderma type III 0 trials
Most studied deeper sub-types
-
Could a cancer pill ease rare, painful skin diseases?
Disease control Not yet recruitingThis early-phase trial tests whether low doses of erlotinib, a drug originally used for cancer, can improve symptoms of rare genetic skin conditions called keratinopathies. About 44 adults with confirmed diagnoses will take increasing doses over 24 weeks. The goal is to see if it…
Phase 1/2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a supplement boost prostate cancer treatment?
Disease control Not yet recruitingThis early-phase trial tests whether adding a dietary supplement called LC-K76 to standard hormone therapy is safe for men with metastatic hormone-sensitive prostate cancer. Forty men will receive the supplement plus hormone therapy for 24 weeks, then be followed for another 24 w…
Early phase 1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New test may predict prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study looks at whether a test called minimal residual disease (MRD) can help predict how well treatment works in men with metastatic hormone-sensitive prostate cancer. Researchers will track 50 newly diagnosed patients to see how different gene patterns affect treatment resp…
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC